Daratumumab-Based Therapy for Newly Diagnosed Myeloma: Patient-Reported Outcomes From MAIA Trial
Posted: Wednesday, March 10, 2021
The combination of daratumumab, lenalidomide, and dexamethasone (D-Rd) appears to be associated with better health-related quality-of-life outcomes compared with lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible, newly diagnosed multiple myeloma, according to patient-reported outcomes from the phase III MAIA study.
“D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in patient-reported outcomes, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline Eastern Cooperative Oncology Group [ECOG] status, or depth of treatment response,” stated Katja Weisel, MD, of the University Medical Center Hamburg, Germany, and colleagues. Their findings were published in the Journal of Clinical Oncology.
In this multicenter study, 737 patients with transplant-ineligible, newly diagnosed multiple myeloma were randomly assigned to receive D-Rd (n = 368) or Rd (n = 369). The European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30-item and the EuroQol 5–dimensional descriptive system assessed patient-related outcomes at baseline and every 3 months during treatment.
Compliance with the patient-related outcomes assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. The Core 30-item global health status scores improved from baseline in both groups but were consistently higher with D-Rd at all time points; the patient-related outcome improvements observed on the EuroQol 5–dimensional descriptive system were similar.
Treatment with D-Rd was associated with a significantly greater reduction in pain scores as early as cycle 3 compared with Rd (P = .0007). This reduction in pain was sustained through cycle 12. Pain reduction with D-Rd was clinically meaningful in patients regardless of age, ECOG status, or depth of response.
Disclosure: For full disclosures of the study authors, visit ascopubs.org.
